Who is sponsoring NCT03631563?

NCT03631563 is sponsored by Fujian Medical University.

What drugs are being tested in NCT03631563?

Interventions in NCT03631563: Immunosuppressive Agent.

What condition does NCT03631563 study?

NCT03631563 studies GVHD in the Setting of Haplo-HSCT.

Is NCT03631563 still recruiting?

NCT03631563 is currently status unknown. Last updated 15 August 2018.

Last reviewed 2018-08-15 · How we verify

NCT03631563

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATG-F VS ATG for the Prevention of GVHD

Status unknown Phase 2, PHASE3 Last updated 15 August 2018

What this trial tests

Phase 2, PHASE3 trial testing Immunosuppressive Agent in GVHD in the Setting of Haplo-HSCT in 120 participants. Status unknown.

Timeline

1 March 2013

Primary endpoint
1 December 2018

1 December 2020

Quick facts

Lead sponsor	Fujian Medical University
Phase	Phase 2, PHASE3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 March 2013
Primary completion	1 December 2018
Estimated completion	1 December 2020
Sites	1 location across China

Drugs / interventions tested

Immunosuppressive Agent — full drug profile →

Conditions studied

GVHD in the Setting of Haplo-HSCT — all drugs for GVHD in the Setting of Haplo-HSCT →

Sponsor

Fujian Medical University

Who can join

Under 65, any sex, with GVHD in the Setting of Haplo-HSCT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.The study aims to compare the efficacy and safety of ATG-F vs ATG, incorporated into the preparative regimens for haplo-identical transplants.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults.
Gatza E, Reddy P, Choi SW. · · 2020 · cited 41× · PMID 31931115 · DOI 10.1016/j.bbmt.2020.01.004
How to improve the outcomes of elderly acute myeloid leukemia patients through allogeneic hematopoietic stem cell transplantation.
Jiang S, Yan H, Lu X, Wei R, et al · · 2023 · cited 1× · PMID 37207218 · DOI 10.3389/fimmu.2023.1102966

Verify or expand the search:

Other Fujian Medical University trials

Trials by the same sponsor.

NCT07314203 — Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastr · Phase 3 · not yet recruiting
NCT07491263 — Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Le · Phase 1 · not yet recruiting
NCT07275034 — A Virtual Reality-Based Horticultural Planting Program for Elderly With Subthreshold Depression · NA · not yet recruiting
NCT07383909 — Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery · NA · recruiting
NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03631563 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University
Last refreshed: 15 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03631563.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing